Maraviroc + Boceprevir = Precautionary

Effect on Concentration

Maraviroc
Increase
Applies within class?
No
Boceprevir
No change
Applies within class?
No

Pharmacologic Effects

Maraviroc
Effect
N/A
Applies within class?
No
Boceprevir
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 17-Jul-2018

Summary

Sources

Maraviroc versus Boceprevir ^

Study Design

In an open-label, fixed-sequence study, 14 healthy subjects received maraviroc (MVC) 150 mg twice daily for 5 days (period 1), followed by coadministration of MVC 150 mg twice daily and boceprevir (BOC) 800 mg 3 times daily for 10 days (period 2).PK was analyzed on day 5 of period 1 and day 10 of period 2.

Study Results

When BOC 800 mg three times daily was administered concurrently with MVC 150 mg twice daily in 14 healthy subjects, geometric mean ratios (GMRs; MVC+BOC/MVC) [90% CIs] of AUC and Cmax for MVC were 3.02 [2.53, 3.59] and 3.33 [2.54, 4.36], respectively.Another small study in healthy subjects (n=5) similarly reported 2.7-fold increase in maraviroc AUC when MVC 150mg daily was administered to subjects receiving BOC 800mg 3 times daily.

Study Conclusions

Concomitant administration of BOC and MVC resulted in increased MVC AUC and plasma concentrations.Recommended dosage of MVC is 150 mg twice daily in patients receiving BOC.

References

Vourvahis M, Plotka A, Kantaridis C, Fang A, Heera J. The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers. Journal Of The Acquired Immunodeficiency Syndromes . 2014; 5: 564-570.